Form 4 for EW Edwards Lifesciences
Accepted 2023-06-13 00:00:00 ET · period of report 2023-06-13 · accession 0001225208-23-006806 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-13 | 2023-06-13 | EW | Szyman Catherine M. | CVP, Critical Care | S - Sale+OE | $85.81 | -5,000 | 35.1K | -12% | -$429.1K |
| D | 2023-06-13 | 2023-06-13 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $36.75 | +5,000 | 40.1K | +14% | +$183.8K |
| D | 2023-06-13 | 2023-06-13 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -5,000 | 67.0K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-13 | S | D | 5,000 | $85.81 | 35,055.78 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $85.75 to $86.23 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2023-06-13 | M | A | 5,000 | $36.75 | 40,055.78 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2023-06-13 | M | D | 5,000 | $0.00 | 67,000 | D | $36.75 · 2018-05-11 to 2024-05-10 | 5,000 Common Stock |